Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Carmen Areses Manrique"'
Autor:
David Arias Ron, Carmen M. Labandeira, María Carmen Areses Manrique, Paula Sampedro Domarco, Ihab Abdulkader, Jesús García-Mata, Christian Rolfo, Diego González-Rivas, Jose Luis Fírvida
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy,
Externí odkaz:
https://doaj.org/article/0227a4fb32734cf9aced213326d3f9b3
Autor:
Aurora Rodríguez, Mª Carmen Areses Manrique, Felipe Couñago, Jose Luis Fírvida, Xabier Mielgo, Juan Zafra, Juan Carlos Trujillo Reyes, Rodolfo Chicas-Sett, Amalia Sotoca, Javier Ras Luna
Publikováno v:
World Journal of Clinical Oncology
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Immunotherapy has represented one of the main medical revolutions of recent decades, and is currently a consolidated treatment for different types of tumors at different stages and scenarios, and is present in a multitude of clinical trials. One of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea9d9df3a0deb7c45fc3a2d776f4469
https://hdl.handle.net/11268/11656
https://hdl.handle.net/11268/11656
Autor:
Rocio Vilchez Simo, Maria Carmen Areses Manrique, María Rosario García Campelo, Cristina Azpitarte Raposeiras, Jose Muñoz Iglesias, Joaquín Martínez, Urbano Anido Herranz, F.J. Afonso, Natalia Fernández Núñez, David Arias Ron, Begoña Campos Balea, Martin Lázaro Quintela, Juan Ruiz Bañobre, Jorge García González, Margarita Amenedo Gancedo, Lucía Santomé Couto, José Luis Fírvida Pérez, Joaquin Casal Rubio, Jesús García Mata, Guillermo Alonso-Jaudenes Curbera, Iria Carou Frieiro
Publikováno v:
Journal of geriatric oncology. 12(3)
Background Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f0359c9eb9f002de01c36c87004c8
https://pubmed.ncbi.nlm.nih.gov/33357975
https://pubmed.ncbi.nlm.nih.gov/33357975
Autor:
Juan Ruiz-Bañobre, José Luis Fírvida Pérez, N. Fernández-Núñez, L. Crama, Martín Lázaro-Quintela, Francisco J. Afonso-Afonso, Pedro Ruiz-Gracia, Jorge García-González, Diego Pérez Parente, Margarita Amenedo-Gancedo, María Del Carmen Areses-Manrique, Lucía Santomé-Couto, Luis León-Mateos, Begoña Campos-Balea, Joaquín Casal-Rubio
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 2093, p 2093 (2020)
Journal of Clinical Medicine
Journal of Clinical Medicine
The combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors with chemotherapy has emerged as a promising therapeutic option for advanced non-small-cell lung cancer (NSCLC). The aim of this meta-analysis was to evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d982e59727b6939f5f52526f8a8378eb
https://www.mdpi.com/2077-0383/9/7/2093
https://www.mdpi.com/2077-0383/9/7/2093
Autor:
Juan Ruiz-Bañobre, Sergio Vázquez, María Del Carmen Areses-Manrique, Lucía Santomé, Jorge García-González, Cristina Azpitarte-Raposeiras, Noemí de Dios-Álvarez, N. Fernández-Núñez, Rosario García-Campelo, Joaquín Mosquera-Martínez, Alexandra Cortegoso, Jose L. Fírvida-Pérez, Joaquín Casal-Rubio, Margarita Amenedo, Francisco J. Afonso-Afonso
Publikováno v:
Transl Lung Cancer Res
The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd6469ae566fac2ed3db43ea72e77b3
https://pubmed.ncbi.nlm.nih.gov/32953477
https://pubmed.ncbi.nlm.nih.gov/32953477
Autor:
Wenxia Qian, Gaohua Feng, Yadong Lu, Xiaoling Lu, Yufang Feng, Chunping Ma, Junyi Ye, Carmen Areses Manrique
Publikováno v:
Journal of Thoracic Disease. 10:5904-5912
Background: The utilization of cancer-linked genetic alterations for categorizing patients against optimal treatment is becoming increasingly popular, especially in non-small cell lung cancer (NSCLC). However, disadvantages of the conventional techni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74fc42c7d0293a01ee20e6265e97c173
https://doi.org/10.21037/jtd.2018.09.108
https://doi.org/10.21037/jtd.2018.09.108
Autor:
Natalia Fernández Núñez, Martin Lázaro Quintela, Iria Carou Frieiro, Joaquin Mosquera Martinez, Margarita Amenedo Gancedo, Joaquin Casal Rubio, Jose Muñoz Iglesias, Alexandra Sabela Cortegoso mosquera, Rocio Vilchez Simo, Urbano Anido Herranz, Jesús García Mata, Lucía Santomé Couto, Begoña Campos Balea, Mª Carmen Areses Manrique, Jorge García González, Mª Rosario García Campelo, Guillermo Alonso-Jaudenes Curbera, José Luis Fírvida Pérez, Cristina Azpitarte Raposeiras, F.J. Afonso
Publikováno v:
Translational Lung Cancer Research. 7:404-415
Background Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc7bb30d30b4aba37c3cf312d55b53a
https://doi.org/10.21037/tlcr.2018.04.03
https://doi.org/10.21037/tlcr.2018.04.03
Autor:
Antonio Iglesias Rey, Ana Cabezón Álvarez, Antonio Javier Jiménez López, Begoña Soler López, Leticia Iglesias Rey, Miguel Ángel Núñez Viejo, Carmen Areses Manrique
Publikováno v:
Trends in Medicine. 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d86efb4b9e90cf9afccc7f42f05607c9
https://doi.org/10.15761/tim.1000198
https://doi.org/10.15761/tim.1000198
Publikováno v:
Gastroenterología y Hepatología. 39:429-432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af569d357a867ac0e3ffa4fb93af54f2
https://doi.org/10.1016/j.gastrohep.2015.11.005
https://doi.org/10.1016/j.gastrohep.2015.11.005
Autor:
Cristina Azpitarte Raposeiras, Noemi De Dios Alvarez, Jorge Garcia, Vanesa Varela Pose, Martin Lázaro Quintela, Victor Cebey, F.J. Afonso, Manuel Constenla, Maria Carmen Areses Manrique, Sara Agraso Busto, Margarita Amenedo, Natalia Fernández Núñez, J. L. Fírvida, Begoña Campos Balea, Juan Ruiz Bañobre, Nazaret Quiroga Veiga
Publikováno v:
Journal of Clinical Oncology. 37:e20636-e20636
e20636 Background: First or second line crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with NSCLC ALK positive and it was the first approved ALK inhibitor. However, there are limited data describing the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::931f32177dca505fc3aa9a66449d847c
https://doi.org/10.1200/jco.2019.37.15_suppl.e20636
https://doi.org/10.1200/jco.2019.37.15_suppl.e20636